Takeda Pharmaceutical Co Ltd ADR
$ 14.28
-0.21%
04 Dec - close price
- Market Cap 47,520,281,000 USD
- Current Price $ 14.28
- High / Low $ 14.42 / 14.26
- Stock P/E 204.00
- Book Value 4514.26
- EPS 0.07
- Next Earning Report 2026-01-29
- Dividend Per Share $198.00
- Dividend Yield 4.65 %
- Next Dividend Date -
- ROA 0.02 %
- ROE N/A %
- 52 Week High 15.35
- 52 Week Low 12.24
About
Takeda Pharmaceutical Company Limited (Ticker: TAK) is a premier global biopharmaceutical firm based in Tokyo, Japan, recognized for its innovative approach to developing and commercializing therapeutic solutions in oncology, gastroenterology, and neuroscience. With a commitment to advancing healthcare, Takeda capitalizes on its extensive research and development capabilities to bring forth transformative therapies that meet critical patient needs. The company is dedicated to sustainability and enhancing patient outcomes worldwide, supported by a robust pipeline and a strategic focus on the ever-evolving pharmaceutical market, reinforcing its leadership position in the industry.
Analyst Target Price
$17.59
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-30 | 2025-05-08 | 2025-01-30 | 2024-10-31 | 2024-07-31 | 2024-05-09 | 2024-02-01 | 2023-10-26 | 2023-07-27 | 2023-05-22 | 2023-02-02 |
| Reported EPS | -0.0253 | 151 | -0.2276 | 0.0478 | 29.07 | 0.1923 | -0.0065 | 33.79 | -15.5 | 28.76 | 0.074 | 0.2927 |
| Estimated EPS | 0.151 | 0.2006 | -0.166 | 0.63 | 87.45 | 0.1228 | -0.0142 | 0.1085 | 0.1441 | 18.62 | 0.0505 | 0.29 |
| Surprise | -0.1763 | 150.7994 | -0.0616 | -0.5822 | -58.38 | 0.0695 | 0.0077 | 33.6815 | -15.6441 | 10.14 | 0.0235 | 0.0027 |
| Surprise Percentage | -116.755% | 75174.1775% | -37.1084% | -92.4127% | -66.7581% | 56.5961% | 54.2254% | 31042.8571% | -10856.4192% | 54.4576% | 46.5347% | 0.931% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-01-29 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Dec 2025 | Jul 2025 | Dec 2024 | Jul 2024 | Dec 2023 | Jul 2023 | Dec 2022 | Jul 2022 | Jul 2021 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2025-12-11 | 2025-07-07 | 2024-12-12 | 2024-07-08 | 2023-12-11 | 2023-07-10 | 2022-12-12 | 2022-07-11 | 2021-07-12 | None |
| Amount | $0.322144 | $0.33901 | $0.326079 | $0.292214 | $0.319068 | $0.30996 | $0.329553 | $0.330062 | $0.406627 | $0.4191 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TAK
2025-11-02 23:22:07
Takeda Pharmaceutical Co. has advised its 50,000 global employees, including 5,000 in Massachusetts, to work from home due to the new coronavirus. Employees in labs or manufacturing must maintain social distancing and limit gatherings to prevent spread, while non-essential business travel is canceled until May 31. The company is also working to develop a medicine for COVID-19, aiming for availability within nine to eighteen months.
2025-10-19 14:09:55
Takeda Pharmaceutical's stock has shown mixed short-term performance but strong long-term gains, prompting a valuation analysis. While a Discounted Cash Flow (DCF) model suggests the stock is significantly undervalued by 69%, its current Price-to-Earnings (PE) ratio of 47.8x is considerably higher than industry and peer averages, indicating it might be overvalued based on earnings. The article introduces "Narratives" as a personalized tool for investors to assess Takeda's fair value based on their own assumptions and future projections.
2025-10-16 12:30:00
InMed Pharmaceuticals Inc. has announced the appointment of Mr. John Bathery to its Board of Directors, effective immediately. Mr. Bathery brings over 30 years of pharmaceutical industry experience, including corporate development and strategic partnerships from Takeda Pharmaceuticals, making him a key asset for InMed's program advancement and partnership exploration. Concurrently, Mr. Bryan Baldasare will not seek re-election at the upcoming Annual General Meeting due to increasing professional obligations.
2025-10-16 12:04:12
Takeda Pharmaceutical will host an earnings call on Thursday, October 30, 2025, to present its 2nd quarter results for fiscal year 2025. Key participants will include President and CEO Christophe Weber, CFO Milano Furuta, and President of R&D Andy Plump. The webcast will include a presentation and a Q&A session, with simultaneous interpretation in English and Japanese.
2025-10-16 07:21:29
Weiss Ratings has given Takeda Pharmaceutical (NYSE:TAK) a "Hold (C+)" rating. This comes after Zacks Research downgraded the stock to a "strong sell." Institutional investors and hedge funds own 9.17% of the company's stock, with several firms increasing their stakes recently.
2025-10-15 01:31:24
Takeda Pharmaceutical is discontinuing its cell therapy efforts, resulting in a ¥58 billion impairment charge, to reprioritize its portfolio towards small molecules, biologics, and antibody-drug conjugates. This strategic shift aims for faster and broader patient impact, with a focus on advancing late-stage assets like oveporexton for narcolepsy, which is crucial for future revenue growth amidst generic competition. The move highlights Takeda's commitment to innovation and pipeline execution to offset revenue pressures.
